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Abstract
One of the first and most important steps in the metastatic cascade is the loss of cell-cell and cell-matrix interactions. N-
cadherin, a crucial mediator of homotypic and heterotypic cell-cell interactions, might play a central role in the metastasis of
neuroblastoma (NB), a solid tumor of neuroectodermal origin. Using Reverse Transcription Quantitative PCR (RT-qPCR),
Western blot, immunocytochemistry and Tissue MicroArrays (TMA) we demonstrate the expression of N-cadherin in
neuroblastoma tumors and cell lines. All neuroblastic tumors (n = 356) and cell lines (n = 10) expressed various levels of the
adhesion protein. The N-cadherin mRNA expression was significantly lower in tumor samples from patients suffering
metastatic disease. Treatment of NB cell lines with the N-cadherin blocking peptide ADH-1 (Exherin, Adherex Technologies
Inc.), strongly inhibited tumor cell proliferation in vitro by inducing apoptosis. Our results suggest that N-cadherin signaling
may play a role in neuroblastoma disease, marking involvement of metastasis and determining neuroblastoma cell viability.
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Introduction
Neuroblastoma (NB) is the most common extracranial solid
tumor in children and accounts for 8–10% of all childhood
malignancies [1,2]. This neoplasm consists of primitive neuro-
blasts, derived from neural crest cells or sympathogonia.
Approximately 40% of all NB patients suffer metastatic disease
at diagnosis. Despite multimodal therapy, these children have a
poor clinical outcome (5-year survival rate of 30% to 40%) [1].
Although our understanding of the heterogeneous nature of
primary neuroblastoma has significantly improved, the metastatic
process, often responsible for the unfavorable outcome, remains ill
understood [3–6]. Studies on metastatic disease provide evidence
that during this multistep process, loss of adhesion seems to be a
crucial factor [7–9]. It has been shown that cell-cell adhesion
molecules such as cadherins play a crucial role during the
metastatic process. Consequently, those cell-cell interaction
proteins form an interesting target for anti-tumor therapy [10–12].
In humans, the cadherin superfamily of adhesion molecules
consists of more than 80 members. However, the most extensively
studied are epithelial (E-) cadherin and neural (N-) cadherin.
Whereas E-cadherin is mainly found in epithelial cells, promoting
tight cell-cell associations, N-cadherin (CDH2) is primarily found
in neuronal tissues and fibroblasts. Noteworthy, N-cadherin
expression changes are crucial for correct migration of the neural
crest cells during early embryonic development. Downregulation
of N-cadherin on these cells is essential to allow migration away
from the neural tube and contributes to the formation of a diverse
array of tissues such as the peripheral nervous system, melano-
cytes, craniofacial cartilage and bone [13]. Members of the N-
cadherin family are characterized by a large extracellular domain
which mediates calcium dependent homophilic interaction
between cadherins, expressed by neighboring cells [14]. In
addition, interactions between cadherins and other receptors such
as Fibroblast Growth Factor Receptor (FGFR) have been
described [11,15]. Through their highly conserved cytoplasmatic
tail, cadherins bind catenins, linking them to the actin-based
cytoskeleton [16].
It is generally accepted that metastasis is preceded by the loss of
E-cadherin mediated cell-cell adhesion [17,18]. The loss of E-
cadherin is often accompanied by de novo expression of N-cadherin,
promoting cell motility and migration. Together, these observa-
tions have been denominated ‘the cadherin switch’. In addition to
promoting motility and migration, N-cadherin homophilic inter-
action between tumor cells and surrounding tissue (e.g. stroma,
endothelium) has been shown to facilitate the transit and survival
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of tumor cells in distant organs [19–21]. Thus, N-cadherin might
be an ideal drug target as inhibition might prevent tumor
metastasis [22]. Examples of invasive tumors where N-cadherin
is downregulated have also been identified. In osteosarcoma, N-
cadherin inhibits cell migration and the formation of metastasis
[23,24]. Similarly, in ovarian carcinoma, N-cadherin is expressed
during different stages, although, one report mentioned that
mucinous cystadenomas are N-cadherin negative [25].
ADH-1 (Exherin, Adherex Technologies Inc.) is a novel cyclic
pentapeptide which contains a cell adhesion recognition site (His-
Ala-Val) important for N-cadherin interaction. Previous reports
showed that peptides containing this sequence disrupt cell
adhesion, induce apoptosis, and alter the intracellular distribution
of b-catenin and actin in endothelial cells. Moreover, ADH-1 has
been evaluated as an anti-tumor agent in vivo in phase I clinical
trials [26–29].
In this study, we tried to unravel the role of N-cadherin in the
metastatic process of neuroblastoma cells by examining the N-
cadherin gene and protein expression in NB cell lines and primary
tumors. N-cadherin expression was confirmed in all tumors and
cell lines. Interestingly, low N-cadherin expression was significant-
ly associated with metastatic disease. Inhibition of the N-cadherin
function by the specific peptide inhibitor ADH-1 strongly
provoked apoptosis of NB cell lines.
Materials and Methods
Patients and cell lines
The patient samples analyzed by RT-qPCR, represent a
selection of the sample set previously described by Vermeulen
et al. [30]. Patient characteristics are summarized in Table 1. The
NB patients were diagnosed and staged according to the
International Neuroblastoma Staging System (INSS) [31]. The
ethical committee (Ethical Committee Ghent University Hospital)
approved the study and written informed consent was obtained
from the patients and/or their parents.
Ten NB cell lines (CLB-GA, IMR32, SH-SY5Y, SK-N-BE(1n),
SK-N-BE(2c), SK-N-FI, STA-NB-10, SJ-NB-10, SHEP and SK-
N-SH) were included in this study (See Table S1). As controls,
HCA2-hTERT fibroblasts (kindly provided by C. Jones, Cardiff
University, UK) and MCF-7 epithelial cell cultures (ACC115,
DSMZ, Germany) were used. Cells were cultured in RPMI 1640
medium supplemented with 15% fetal calf serum, 2 mM
glutamine, 100 IU/mL penicillin, and 100 mg/mL streptomycin
(medium and supplements from Gibco–Invitrogen, Merelbeke,
Belgium) in a humidified atmosphere with 5% CO2 at 37uC.
Immunocytochemistry
Cytospins were immunocytochemically stained as described
previously [32]. Briefly, large diameter (17 mm) cytospins
containing 56105 cells were incubated with an unlabeled mouse
monoclonal anti-human N-cadherin antibody (clone 3B9, Invitro-
gen, Merelbeke, Belgium). Controls where the primary antibody
was replaced by a non-related IgG1 antibody (Dako Corporation,
Glostrup, Denmark company) were included to evaluate the
background staining. During a second and third incubation step,
cells were incubated with an unlabeled rabbit anti-mouse antibody
(Dako Corporation) and APAAP complexes (Dako Corporation),
respectively. The bound alkaline phosphatase complexes were
stained using the Dako Fuchsin+TM Substrate Chromogene
System (Dako Corporation). Cells were counterstained with
hematoxylin and examined under a light microscope.
Viability assay
Cells were seeded in triplicate in a 96-well plate (200,000 cells
per well), incubated for 6 hours at 37uC and 5% CO2, allowing
them to adhere to the surface. Subsequently, they were treated
with ADH-1 (at 0.25; 0.50 or 1 mg/ml) for 12, 24, or 48 hours.
Cell viability was determined using the CellTiter-Glo Luminescent
Cell Viability Assay (Promega, Madison, WI) according to the
manufacturer’s protocol and luminescence measured using the
LUMIstar Optima plate reader (BMG Labtech, Offenburg,
Germany). Effects on cell death were confirmed using flow
cytometric Annexin V staining. Briefly, cells were resuspended in
200 ml Annexin V buffer (Bender MedSystems, Vienna, Austria),
supplemented with 1 ml Annexin V-FITC (Bender MedSystems)
and incubated during 15 minutes in the dark at room tempera-
ture. Another 100 ml Annexin V buffer was added, supplemented
with 4 ml Propidium Iodide (PI) (Beckman Coulter, Woerden, The
Netherlands). Analysis was performed on a Cytomics FC-500 flow
cytometer (Beckman Coulter).
RNA extraction
Total RNA was extracted from 56106 to 16107 cells using
RNeasy mini columns (Qiagen, Venlo, The Netherlands) following
the instructions of the manufacturer. The concentration and purity
of the recovered RNA was determined measuring the optical
density (OD) at 260 and 280 nm. RNA quality was defined using
the Experion RQI value. All RNA was DNase treated to remove
contaminating genomic DNA. Briefly, 1 mg of RNA was incubated
with 1 ml of 106 DNase I reaction buffer and 1 ml of DNase I
(Invitrogen, Merelbeke, Belgium) for 15 minutes at room temper-
ature. DNase I was inactivated by adding 1 ml of 25 mM EDTA
solution and heating 10 minutes at 65uC.
Table 1. Summary of patient characteristics.
qPCR cohort
(n=356)
TMA cohort
(n=84)*
Age (months)
Median (range) 10.7 (0–163) 16 (0–153)
Gender
Male 52% (185) 44% (37)
Female 48% (171) 56% (47)
MYCN status
Not amplified 85% (302) 75% (63)
Amplified 13% (47) 13% (11)
Duplicated 2% (7) 1% (1)
INSS stage
Stage 1 35% (124) 23% (19)
Stage 2 16% (58) 17% (14)
Stage 3 17% (59) 11% (9)
Stage 4 22% (80) 29% (24)
Stage 4S 10% (35) 5% (4)
Follow-up
Relapse/progression 35% (126) 40% (34)
CCR 65% (230) 60% (50)
*Remark that not for all patients included in the TMA cohort complete
information was available.
doi:10.1371/journal.pone.0031206.t001
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Reverse transcription quantitative PCR
cDNA was generated using the iScript cDNA synthesis kit (Bio-
Rad, Nazareth Eke, Belgium) according to the instructions of the
manufacturer. Reactions were performed using 2 mg DNase I –
treated RNA. After cDNA preparation, the samples were diluted
10-fold and stored at 280uC in 50 ml volumes. RT-qPCR
reactions were carried out using MESA GREEN qPCR
Mastermix Plus (Eurogentec, Seraing, Belgium). Briefly, 2 ml
cDNA was added to 23 ml of PCR mix (6.25 ml Reaction Buffer,
0.25 ml Forward Primer (600 nM), 0.25 ml Reverse Primer
(600 nM) and 16.25 ml milliQ water). Reactions were carried
out on an iQ5 real-time qPCR machine (Bio-Rad). Relative
expression values were calculated using the DCt-method. For
normalization, the expression of at least three reference genes was
combined to calculate a normalization factor [33]. RT-qPCR
analysis performed on the SIOPEN cohort was performed as
described in Vermeulen et al. [30] and analyzed using the
qbasePLUS 1.4 software (http://www.qbaseplus.com). Primer
sequences were as follows: Fwd-CDH2: TCCAGACCCCAATT-
CAATTAATATTAC; Rev-CDH2: AAAATCACCATTAAGC-
CGAGTGA and the reference genes: FWD-B2M: GAGTA-
TGCCTGCCGTGTG; REV-B2M: AATCCAAATGCGGCA-
TCT; FWD-SDHA: TGGGAACAAGAGGGCATCTG; REV-
SDHA: CCACCACTGCATCAAATTCATG; FWD-UBC: AT-
TTGGGTCGCGGTTCTTG; REV-UBC: TGCCTTGACAT-
TCTCGATGGT; FWD-HPRT1: TGACACTGGCAAAACAA-
TGCA and REV-HPRT1: GGTCCTTTTCACCAGCAAGCT.
Primer sequences were submitted to RTPrimerDB database
(http://www.rtprimerdb.org).
Tissue Microarray Analysis
For the establishment of the tissue microarray, three repre-
sentative areas (0.6 mm diameter) were selected from H&E
stained slides of 84 formalin-fixed and paraffin-embedded
primary untreated NB tumors of which sufficient clinical data
were available (Table 1). Each of the three cores were embedded
into a paraffin array multiblock (for layout, see Figure S2).
Sections of 1.5 mm thickness were cut and transferred to
positively charged glass slides, dried overnight at 37uC, dewaxed,
and rehydrated by routine methods. Immunohistochemistry was
performed on three such slides, using a peroxidase-labeled mouse
monoclonal anti-human N-cadherin antibody (clone 3B9, Invi-
trogen, Merelbeke, Belgium) and the 3-amino-9-ethylcarbazole
(AEC) substrate. An additional slide served as negative control.
The immunostainings were evaluated by one experienced
pathologist (K.B). First, tissue spots were checked for their
presence, completeness or possible artifacts and those meeting
these qualitative criteria were chosen for reporting the staining
results. Slides were scored for immunoreactive neuroblasts,
gangliocytic differentiated cells and neuropil. The following
semi/quantitative scoring system was used: no staining = 0; weak
staining = 1; moderate staining = 2 and strong staining = 3 and
applied on each of the three histological targets. In case of
heterogeneous staining patterns, subpopulations of different
staining intensity were taken into account by adding or
subtracting (according to their intensity compared to the main
population) 0.3 points from the initial value (since most of the
subpopulations represented ,30% of the immunoreactive cells).
Subsequently these results were averaged over all graded
histological targets in a spot and all triplicates. After six months,
all spots were evaluated once more by the same observer, without
knowledge of the first results. The final results used for statistical
analysis represent average scores from both evaluations.
Western blotting
Exponentially growing cells were harvested and lysed in lysis
buffer (50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 1% NP-40
(Sigma, Bornem, Belgium), 1% Triton X-100 (Sigma) and
protease inhibitor cocktail tablets (Roche, Vilvoorde, Belgium)).
Cleared lysates were assayed for protein concentration by using
the Bio-Rad (Hemel Hempstead, Hertis, United Kingdom) protein
assay system and subjected to immunoblotting. Bound primary
antibodies were detected with horseradish peroxidase (HRP)–goat
anti-mouse antibody (Amersham Pharmacia Biotech, Uppsala,
Sweden). Enhanced chemiluminescence Western blotting detec-
tion reagents were purchased from Amersham. The following
primary antibodies were used: a mouse monoclonal anti-human
N-cadherin antibody (clone 3B9, Invitrogen, Merelbeke, Belgium)
and a mouse anti-alpha tubulin (Sigma, 1/4000).
Statistical analysis
Analysis of cell viability data was performed using GraphPad
Prism software version 5.01 for Windows (GraphPad Software,
San Diego, CA). All other statistics were performed in SPSS
version 15 for Windows (SPSS, Chicago, IL). Study populations
were described by standard descriptive statistics. Differences in
expression (RNA, protein) between patient groups (non-metastatic
vs. metastatic; high risk vs. low risk; favorable vs. unfavorable
prognosis) were analyzed by the non-parametric Mann-Whitney U
test. All statistical tests were two-sided. P-values less than 0.05 were
considered statistically significant.
Results
N-cadherin expression in neuroblastoma cell lines
We first quantified the N-cadherin mRNA expression across a
panel of 10 NB cell lines. Table S1 lists their general
characteristics. Relative quantification of N-cadherin mRNA
levels using RT-qPCR showed that all NB cell lines expressed
N-cadherin (Fig. 1A), with the highest mRNA levels observed in
IMR32 and SH-SY5Y cells. Gene expression data were confirmed
by Western blot (Fig. 1B) and semi-quantitative analysis of the
blots revealed that high protein expression was observed in SK-N-
BE(2c), SK-N-FI, STA-NB-10 and CLB-GA cells (Fig. 1C).
Immunocytochemical staining for N-cadherin further evidenced
the N-cadherin expression in different NB cell lines at varying
levels (Fig. 1D).
N-cadherin expression correlates with metastatic disease
Next, we studied the N-cadherin mRNA expression in a sample-
set of 356 neuroblastoma tumors. Table 1 shows the clinical details
of the patients. According to the International Neuroblastoma
Staging System (INSS), 77 patients were classified with a stage 4
tumor and 35 patients were diagnosed with stage 4S disease. Both
stage 4 and 4S patients suffer from metastatic disease at diagnosis.
By means of RT-qPCR, we detected N-cadherin mRNA
expression in all 356 primary tumor samples (Figure S1), as was
previously reported by Amitay and colleagues [34]. In an effort to
associate N-cadherin expression with clinical parameters, the
relation between N-cadherin expression and metastatic disease
was evaluated. Since the N-cadherin mRNA expression was not
normally distributed (Kolmogorov-Smirnov test, p,0.001), non-
parametric statistical tests (Mann-Withney U, Kruskall-Wallis)
were used. The median relative expression level was significantly
lower in metastasized NB tumors (stage 4 and 4S) compared to
localized tumors (stages 1, 2 and 3) (p = 0.006). Moreover, patients
with high risk disease (stage 4.1 year and stage 1, 2, 3 and 4S
patients with MYCN amplification) presented with a lower
N-Cadherin in Neuroblastoma Disease
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31206
N-cadherin expression (p = 0.048) compared to low risk patients
(Fig. 2A and B).
Next, we investigated the observed reduced expression of N-
cadherin in metastatic high risk NB at the protein level using a
dedicated Tissue MicroArray (TMA). A total of 84 paraffin
embedded tumors, of which sufficient clinical information was
available, were selected for this purpose. The general character-
istics of the 84 patients are summarized in Table 1. To obtain an
adequate representation of the whole sections, 3 punches from
each of the 84 tumors were embedded in the paraffin array block,
followed by sectioning. A schematic view on the array is given in
Figure S2. Three independent slices of the paraffin array block
were stained for N-cadherin protein expression. In agreement with
the RT-qPCR data, the N-cadherin protein was detected in all
punches, albeit at different levels (Figure 3). We further classified
the N-cadherin protein expression according to the quartile ranges
of the expression data into weak, moderate and strong expression
(see Materials and methods). For further analyses, we only took
into account the primary tumor samples present on the TMA
(N=73). As observed for mRNA expression, N-cadherin protein
expression was significantly lower in metastasized primary NB
tumors compared to non-metastasized tumors (Fisher’s Exact Test,
p = 0.012) (Figure 4). Patients with high risk disease presented with
a lower N-cadherin protein expression (p = 0.032). Interestingly,
we observed that N-cadherin expression significantly correlated
with the recorded INPC prognosis (favorable vs. unfavorable
status), where low N-cadherin expression predicts an unfavorable
status (p = 0.004).
Functional inhibition of N-cadherin decreases cell
viability
In order to study the functional role of N-cadherin in NB-cells, a
N-cadherin antagonistic model was established by addition of
ADH-1 to NB cell lines. ADH-1 inhibits N-cadherin mediated
interactions. Moreover, ADH-1 is known to induce apoptosis and
alter the intracellular distribution of b-catenin and actin in
endothelial cells [26–29].
Erez et al. reported that ADH-1 induces apoptosis in endothelial
cells when applied at concentrations greater than 0.25 mg/ml
[35]. These data led us to examine the dose dependent effect of
ADH-1 on NB cell lines (CLB-GA, IMR32, SK-N-SH), fibroblasts
and epithelial cell cultures. The number of viable cells in culture
was measured using the CellTiter-Glo luminescent Cell Viability
assay (Promega) at 12 h, 24 h and 48 h after addition of ADH-1
(0.25 mg/ml; 0.50 mg/ml and 1 mg/ml). ADH-1 proved to be a
potent inducer of cell death in NB cell lines when added at 1 mg/
ml. At this concentration, more than 50% of NB cells underwent
cell death 24 h after addition (Fig. 5). Interestingly, no effect was
seen on the survival of fibroblasts and N-cadherin negative
epithelial cells (Fig. 5). These observations were confirmed by flow
cytometric determination of PI and FITC-Annexin V levels
(Figure S3).
Figure 1. Expression of N-cadherin transcript in NB cell lines. A. gene expression was measured across a panel of 10 human NB-derived cell
lines using quantitative RT-qPCR. Values were normalized to the B2M and UBC housekeeping genes. The DCt method was used for relative
quantification. Data are mean 6 standard deviation (n = 3). B. Western blot showing protein expression of N-cadherin across the 10 cell lines. a-
tubulin was used as a loading control, shown below the N-cadherin blot. C. Relative quantification of N-cadherin protein expression. Protein
expression was normalized to the a-tubulin loading control. D. Immunocytochemical staining of NB cell lines, confirming protein expression. Images
taken at 1006magnification.
doi:10.1371/journal.pone.0031206.g001
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Discussion
The acquisition of invasive and metastatic properties by cancer
cells during tumor progression is intimately linked to changes in
the expression of adhesion molecules regulating the interactions of
cancer cells with the extracellular matrix (ECM) and neighboring
cells [17–21]. At present, only little information on the importance
of N-cadherin expression in neuroblastoma, is available.
In this study, we have shown that N-cadherin transcript and
protein expression can be detected in all NB cell lines and NB
Figure 2. N-cadherin mRNA levels negatively correlate to metastasis and risk definition. A. N-cadherin mRNA expression and the
presence/absence of metastasis at diagnosis. B. N-cadherin mRNA expression according to risk group (high risk vs. others). The median (horizontal
line), the interquartile range (box), and the upper and lower range of the data (whiskers) are shown.
doi:10.1371/journal.pone.0031206.g002
Figure 3. Immunohistochemical expression of N-cadherin on TMA. Immunohistochemical staining was performed and results scored as
described in Materials and Methods. Images are representative for strong (a), moderate (b) to weak level (c) or, in one case, negative staining (d).
Note: All four tumors are stained simultaneously on the same TMA slide facilitating a comparison of staining intensities. Images were taken with an
660 dry lens and are presented at identical magnification.
doi:10.1371/journal.pone.0031206.g003
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tumor samples. However no clear correlation was observed
between RNA and protein levels in the different cell lines. Lack
of correlation between mRNA and protein levels is often observed
and may result from various post-translational mechanisms.
The observed association between reduced N-cadherin expres-
sion and the presence of metastasis is in accordance with the
biological role of N-cadherin in neural development, where the
absence of N-cadherin expression is a pre-requisite for neural crest
migration and its re-expression correlates with a migration stop.
Remarkably, metastatic outgrowth does not seem to require
extensive alteration in N-cadherin expression levels. This is in line
with the finding of others, demonstrating that the metastatic
process is not accompanied by major changes in gene expression
[3,36]. Nevo and colleagues recently reported 112 genes
differentially expressed between metastatic and non-metastatic
NB cells, using an orthotopic model of a human NB local and
metastatic variant having the same genetic background [3].
Unfortunately, the N-cadherin gene was not represented in their
set of differential genes, possibly due to differences in experimental
setup and data threshold cut off values.
Classical cadherins regulate, amongst others, apoptotic process-
es. For example, N-cadherin-mediated cell adhesion plays a
pivotal role in follicular and luteal cell survival and its disruption
induces apoptosis of these cells in culture [37–39]. Similarly, it was
demonstrated that disruption of cadherin-mediated adhesion in
mouse intestinal epithelial cells leads to cell death [40]. In our
hands, the addition of 1 mg/ml ADH-1 peptide caused significant
apoptotic cell death in all NB cell lines investigated, which was not
seen in N-cadherin negative epithelial cells, neither in fibroblasts.
Moreover, the detection of phosphatidylserine strongly suggests
Figure 4. N-cadherin protein levels correlate with metastatic disease. Visualized is the distribution of samples (percentage) staining weak,
moderate and strong in each class (metastasized N= 34, or non-metastasized tumors N=39). The number of samples in each class was set to 100
percent.
doi:10.1371/journal.pone.0031206.g004
Figure 5. ADH-1 induces cell death in vitro. ADH-1 (1 mg/ml) was added to exponentially growing cultures of epithelial cells, fibroblasts and the
indicated NB cell lines. Cell survival was measured at 12, 24 and 48 h after addition of ADH-1, using the CellTiter-Glo luminescent Cell Viability assay
(Promega). Data were normalized to no drug treatment. Data are mean 6 standard deviation (n = 3).
doi:10.1371/journal.pone.0031206.g005
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that the detected cell death is mainly due to apoptosis. The strong
negative effect on cell viability at this clinically feasible dose,
combined with the expression of N-cadherin in all NB samples,
suggest N-cadherin as a potential novel therapeutic target in the
treatment of NB disease. Moreover, to our knowledge, no N-
cadherin gene deletions, amplifications or mutations, possibly
hampering N-cadherin-based treatment of NB, are described,
offering a broad therapeutic application domain. However, this
needs further investigation, including the effect on cell viability of
all other signaling molecules in the N-cadherin pathway. In
addition, recent clinical trials using ADH-1 report low toxicity and
antitumor activity in a variety of cancers including esophageal,
non-small cell lung, renal cell and hepatocellular carcinomas [26–
29]. While preparing this manuscript, Adherex set off a screen for
small molecule N-cadherin antagonists, principally having struc-
tural similarities to the HAV region of N-cadherin. Burden-Gulley
and colleagues demonstrated that those novel compounds are even
more potent than ADH-1 at perturbing N-cadherin-mediated
neurite outgrowth and cell adhesion [41]. Concerning their higher
potency, and their longer half-life compared to the ADH-1
peptide, it will be of high interest to evaluate their impact on N-
cadherin mediated apoptotic cell death in NB cells.
At first glance, it may seem paradoxical that low N-cadherin
levels correlate with metastatic disease, and on the other hand
inhibition of N-cadherin signaling results in apoptotic cell death.
However, the in vitro experiments clearly indicate that neuro-
blastoma cells are sensitive to apoptosis, here stimulated by ADH-
1, an inhibitor of N-cadherin. This however also could implicate
that cells which do harbor only low levels of N-cadherin are less
sensitive to apoptosis induction, allowing them to circumvents
signals of death provoked by losing contact signals. In other words,
together our experiments could indicate that, low expression of N-
cadherin implicates a higher apoptosis resistance and with this the
possibility of metastasis.
In summary, we have demonstrated that low N-cadherin
expression strongly correlates with the metastatic dissemination
of NB tumors. Importantly, our functional experiments showed
that the N-cadherin antagonist ADH-1 has significant antitumor
activity against neuroblastoma cells in vitro. Since virtually all
neuroblastoma samples express N-cadherin, the cell adhesion
protein might be a valid target for treatment.
Supporting Information
Figure S1 Real-time RT-qPCR analysis of N-cadherin
expression in 356 NB patients. Gene expression was
measured across a panel of 356 human NB samples using
quantitative real-time RT-PCR. Values were normalized to the
B2M, SDHA and HPRT1 housekeeping genes. The DCt method
was used for relative quantification.
(TIF)
Figure S2 Overview of tissue distribution on the TMA.
(TIF)
Figure S3 ADH-1 induces cell death in vitro. ADH-1
(1 mg/ml) was added to exponentially growing cultures of
fibroblasts and the indicated NB cell lines. Cell survival was
measured at 12, 24 and 48 h after addition of ADH-1, using PI
and Annexin V staining. Data were normalized to no drug
treatment. Data are mean 6 standard deviation (n= 3).
(TIF)
Table S1 NB cell line characteristics. *For immunopheno-
typing, values indicate percentage of cells stained. **DEL=dele-
tion, AMP= amplification
(DOC)
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